Literature DB >> 21403094

Human cardiac stem cell differentiation is regulated by a mircrine mechanism.

Toru Hosoda1, Hanqiao Zheng, Mauricio Cabral-da-Silva, Fumihiro Sanada, Noriko Ide-Iwata, Barbara Ogórek, João Ferreira-Martins, Christian Arranto, Domenico D'Amario, Federica del Monte, Konrad Urbanek, David A D'Alessandro, Robert E Michler, Piero Anversa, Marcello Rota, Jan Kajstura, Annarosa Leri.   

Abstract

BACKGROUND: Cardiac stem cells (CSCs) delivered to the infarcted heart generate a large number of small fetal-neonatal cardiomyocytes that fail to acquire the differentiated phenotype. However, the interaction of CSCs with postmitotic myocytes results in the formation of cells with adult characteristics. METHODS AND
RESULTS: On the basis of results of in vitro and in vivo assays, we report that the commitment of human CSCs (hCSCs) to the myocyte lineage and the generation of mature working cardiomyocytes are influenced by microRNA-499 (miR-499), which is barely detectable in hCSCs but is highly expressed in postmitotic human cardiomyocytes. miR-499 traverses gap junction channels and translocates to structurally coupled hCSCs favoring their differentiation into functionally competent cells. Expression of miR-499 in hCSCs represses the miR-499 target genes Sox6 and Rod1, enhancing cardiomyogenesis in vitro and after infarction in vivo. Although cardiac repair was detected in all cell-treated infarcted hearts, the aggregate volume of the regenerated myocyte mass and myocyte cell volume were greater in animals injected with hCSCs overexpressing miR-499. Treatment with hCSCs resulted in an improvement in ventricular function, consisting of a better preservation of developed pressure and positive and negative dP/dt after infarction. An additional positive effect on cardiac performance occurred with miR-499, pointing to enhanced myocyte differentiation/hypertrophy as the mechanism by which miR-499 potentiated the restoration of myocardial mass and function in the infarcted heart.
CONCLUSIONS: The recognition that miR-499 promotes the differentiation of hCSCs into mechanically integrated cardiomyocytes has important clinical implications for the treatment of human heart failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403094      PMCID: PMC3066266          DOI: 10.1161/CIRCULATIONAHA.110.982918

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  Regulation of hematopoiesis by gap junction-mediated intercellular communication.

Authors:  E Montecino-Rodriguez; K Dorshkind
Journal:  J Leukoc Biol       Date:  2001-09       Impact factor: 4.962

2.  Intense myocyte formation from cardiac stem cells in human cardiac hypertrophy.

Authors:  Konrad Urbanek; Federico Quaini; Giordano Tasca; Daniele Torella; Clotilde Castaldo; Bernardo Nadal-Ginard; Annarosa Leri; Jan Kajstura; Eugenio Quaini; Piero Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-19       Impact factor: 11.205

3.  CD31- but Not CD31+ cardiac side population cells exhibit functional cardiomyogenic differentiation.

Authors:  Otmar Pfister; Frédéric Mouquet; Mohit Jain; Ross Summer; Michiel Helmes; Alan Fine; Wilson S Colucci; Ronglih Liao
Journal:  Circ Res       Date:  2005-06-09       Impact factor: 17.367

4.  Isolation of a mammalian homologue of a fission yeast differentiation regulator.

Authors:  H Yamamoto; K Tsukahara; Y Kanaoka; S Jinno; H Okayama
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

5.  Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.

Authors:  Alma Zernecke; Kiril Bidzhekov; Heidi Noels; Erdenechimeg Shagdarsuren; Lin Gan; Bernd Denecke; Mihail Hristov; Thomas Köppel; Maliheh Nazari Jahantigh; Esther Lutgens; Shusheng Wang; Eric N Olson; Andreas Schober; Christian Weber
Journal:  Sci Signal       Date:  2009-12-08       Impact factor: 8.192

6.  Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure.

Authors:  Konrad Urbanek; Daniele Torella; Farooq Sheikh; Antonella De Angelis; Daria Nurzynska; Furio Silvestri; C Alberto Beltrami; Rossana Bussani; Antonio P Beltrami; Federico Quaini; Roberto Bolli; Annarosa Leri; Jan Kajstura; Piero Anversa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

7.  Cardiac stem cells delivered intravascularly traverse the vessel barrier, regenerate infarcted myocardium, and improve cardiac function.

Authors:  Buddhadeb Dawn; Adam B Stein; Konrad Urbanek; Marcello Rota; Brian Whang; Raffaella Rastaldo; Daniele Torella; Xian-Liang Tang; Arash Rezazadeh; Jan Kajstura; Annarosa Leri; Greg Hunt; Jai Varma; Sumanth D Prabhu; Piero Anversa; Roberto Bolli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-25       Impact factor: 11.205

8.  Myocyte turnover in the aging human heart.

Authors:  Jan Kajstura; Narasimman Gurusamy; Barbara Ogórek; Polina Goichberg; Carlos Clavo-Rondon; Toru Hosoda; Domenico D'Amario; Silvana Bardelli; Antonio P Beltrami; Daniela Cesselli; Rossana Bussani; Federica del Monte; Federico Quaini; Marcello Rota; Carlo A Beltrami; Bruce A Buchholz; Annarosa Leri; Piero Anversa
Journal:  Circ Res       Date:  2010-11-18       Impact factor: 17.367

9.  Sox6 regulation of cardiac myocyte development.

Authors:  Orit Cohen-Barak; Zanhua Yi; Nobuko Hagiwara; Koshiro Monzen; Issei Komuro; Murray H Brilliant
Journal:  Nucleic Acids Res       Date:  2003-10-15       Impact factor: 16.971

10.  Mechanical performance of spared myocytes after myocardial infarction in rats: effects of captopril treatment.

Authors:  J M Capasso; P Anversa
Journal:  Am J Physiol       Date:  1992-09
View more
  97 in total

1.  Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium.

Authors:  Prasanna Krishnamurthy; Melissa Thal; Suresh Verma; Eneda Hoxha; Erin Lambers; Veronica Ramirez; Gangjian Qin; Douglas Losordo; Raj Kishore
Journal:  Circ Res       Date:  2011-09-29       Impact factor: 17.367

2.  Stem cell-based delivery of Hypoxamir-210 to the infarcted heart: implications on stem cell survival and preservation of infarcted heart function.

Authors:  Ha Won Kim; Shujia Jiang; Muhammad Ashraf; Khawaja Husnain Haider
Journal:  J Mol Med (Berl)       Date:  2012-05-31       Impact factor: 4.599

Review 3.  MicroRNAs as novel regulators of stem cell fate.

Authors:  Eunhyun Choi; Eunmi Choi; Ki-Chul Hwang
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 4.  Circulating miR-499 as a potential biomarker for acute myocardial infarction.

Authors:  Yunyi Xin; Chengjian Yang; Zhijun Han
Journal:  Ann Transl Med       Date:  2016-04

Review 5.  Cardiac stem cell niches.

Authors:  Annarosa Leri; Marcello Rota; Toru Hosoda; Polina Goichberg; Piero Anversa
Journal:  Stem Cell Res       Date:  2014-09-08       Impact factor: 2.020

6.  MicroRNA values in children with rheumatic carditis: a preliminary study.

Authors:  Gokhan Gumus; Dilek Giray; Onur Bobusoglu; Lulufer Tamer; Derya Karpuz; Olgu Hallioglu
Journal:  Rheumatol Int       Date:  2018-05-29       Impact factor: 2.631

7.  Targeting miRNA for Therapy of Juvenile and Adult Diabetic Cardiomyopathy.

Authors:  Shyam Sundar Nandi; Paras Kumar Mishra
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 8.  MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine.

Authors:  V Sala; S Bergerone; S Gatti; S Gallo; A Ponzetto; C Ponzetto; T Crepaldi
Journal:  Cell Mol Life Sci       Date:  2013-11-12       Impact factor: 9.261

9.  Stem cells and myocardial regeneration: cooperation wins over competition.

Authors:  Annarosa Leri; Piero Anversa
Journal:  Circulation       Date:  2012-12-05       Impact factor: 29.690

Review 10.  MicroRNAs: a new piece in the paediatric cardiovascular disease puzzle.

Authors:  Ahmed Omran; Dalia Elimam; Keith A Webster; Lina A Shehadeh; Fei Yin
Journal:  Cardiol Young       Date:  2013-02-26       Impact factor: 1.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.